Edition:
United Kingdom

Aslan Pharmaceuticals Ltd (ASLN.OQ)

ASLN.OQ on NASDAQ Stock Exchange Global Market

4.35USD
14 Dec 2018
Change (% chg)

$-0.42 (-8.81%)
Prev Close
$4.77
Open
$4.99
Day's High
$4.99
Day's Low
$4.20
Volume
5,664
Avg. Vol
2,580
52-wk High
$10.41
52-wk Low
$4.20

Summary

Name Age Since Current Position

Carl Firth

2011 Chairman of the Board, Chief Executive Officer

Mark McHale

2011 Chief Operating Officer

Kiran Asarpota

2010 Vice President-Finance

Bertil Lindmark

2015 Chief Medical Officer

Abel Ang

2016 Director

Damien Lim

2016 Director

Jun Wu

2016 Director

Robert Hoffman

2018 Independent Director

Andrew Howden

2016 Independent Director

Qingfeng Sun

2016 Independent Director

Biographies

Name Description

Carl Firth

Mr. Carl Firth has been serving as Chairman of the Board and Chief Executive Officer in ASLAN PHARMACEUTICALS LIMITED since January 1, 2011. He holds a Bachelor's degree in Natural Sciences and a Master's degree in Natural Sciences both from University of Cambridge, the United Kingdom, an Executive Master of Business Administration from London Business School, the United Kingdom, and a Ph.D. in Molecular Biology from University of Cambridge, the United Kingdom. He is also Independent Director in Uni-Bio Science Group Limited, Exploit Technologies Pte Ltd. and Hummingbird Biosciences, as well as Director in Kimba Capital Limited, Liberty Park Music Pte Ltd. and other three companies. He is also a Professor of Duke-NUS Graduate Medical School Singapore.

Mark McHale

Mr. Mark McHale has been serving as Chief Operating Officer in ASLAN PHARMACEUTICALS LIMITED since February 7, 2011. He holds a Bachelor's degree in Biology from University of London, the United Kingdom, and a Ph.D. in Molecular Biology from University of East Anglia, the United Kingdom. He is also Director in Match Point Developments Limited and a Shanghai-based company.

Kiran Asarpota

Mr. Kiran Asarpota has been serving as Vice President-Finance in ASLAN PHARMACEUTICALS LIMITED since November 15, 2010. He holds a Bachelor of Business Administration from Oxford Brookes University, the United Kingdom, and an Master of Business Administration from London South Bank University, the United Kingdom.

Bertil Lindmark

Mr. Bertil Lindmark has been serving as Chief Medical Officer in ASLAN PHARMACEUTICALS LIMITED since March 1, 2015. He holds a Bachelor's degree and a Ph.D. from Lund University, Sweden. He is also Director in a Shanghai-based company.

Abel Ang

Mr. Abel Ang has been serving as Director in ASLAN PHARMACEUTICALS LIMITED since April 15, 2016. He holds a Bachelor's degree in Mass Communications from Nanyang Technological University, Singapore, and a Master's degree in Computational Biology from Rutgers, The State University of New Jersey, the United States. He is also Director in Ultrona Pte Ltd., Exploit Technologies Pte Ltd., Economic Development Innovations Singapore Pte Ltd. (EDIS), Veredus Laboratories Pte Ltd. (Veredus), Advanced Materials Technologies Pte Ltd., Dornier MedTech Asia Pte Ltd. Singapore, Dornier MedTech Japan Co., Ltd. Japan, Dornier MedTech America Inc. America, EDIS Austin Pte Ltd., Symbiosis Ventures Management Sdn Bhd, Galaxis Ventures (S) Pte Ltd., MT Pte Ltd., Executive Director in DMT MedTech GmbH Germany, Dornier MedTech Europe GmbH Germany, Dornier MedTech Laser GmbH Germany, Dornier MedTech Systems GmbH Germany, Dornier GmbH Germany and Singhealth Medical Technology Office Advisory Panel, as well as Chief Operating Officer in Accuron Technologies Limited.

Damien Lim

Mr. Damien Lim has been serving as Director in ASLAN PHARMACEUTICALS LIMITED since April 15, 2016. He holds a Bachelor of Business Administration from University of Houston, the United States. He is also Director in 68 Holdings Pte. Ltd., AFA Management LLC, BioMers Pte. Ltd., BioVeda Capital Pte Ltd., BioVeda Capital Singapore Pte Ltd., BioVeda Fund Pte Ltd., BV Healthcare II Pte. Ltd., Chrysler Jeep Automotive of Singapore Pte Ltd., Clearbridge BSA Pte. Ltd., Excelfin Pte Ltd., ExCL Inc., ExCL (SF) Inc., HRH Merchandise Singapore Pte Ltd., IFC Holdings Pte Ltd., Integrated Food Concepts Pte. Ltd., Ital Auto Pte. Ltd., Karmelitská Hotel s.r.o., Komoco (China) Pte. Ltd., Komoco Car Rentals Pte Ltd., Komoco Holdings Pte Ltd., Komoco Investments Pte Ltd., Komoco Motorcycles Pte. Ltd., Komoco Motors (M) Sdn Bhd, Komoco Motors Pte Ltd., Komoco Properties Pte Ltd., Komoco Trading Pte Ltd., Leisure Ventures Pte Ltd., LV Hotel Investment (West) Pte Ltd., LV Investments (USA) Pte Ltd., LV Resort (Thailand) Pte Ltd., Mach7 Technologies Limited, Mach7 Technologies Pte. Ltd., MBSA Automotive Malaysia Sdn Bhd, Mojo Partners Pte. Ltd., MSC Hotel Investments Coöperatie U.A., Nusantara Jutamas Sdn. Bhd., Presto Television Pte Ltd., Promus Private Limited, Safe Foods Asia Pte. Ltd., Singapore Advanced Biologics Pte. Ltd., The Yamu Club Villa Ltd., The Yamu Limited and Zenith Securities Pte Ltd.

Jun Wu

Jun Wu has been serving as Director in ASLAN PHARMACEUTICALS LIMITED since April 15, 2016. Wu holds a Bachelor's degree in Biology from San Jose State University, the United States, and a Ph.D. from University of California, San Francisco, the United States. Wu is also Director in Alnair Investment, Novoasis Investment Ltd., Optomed Oy, two investment companies, a Suzhou-based company and six Shanghai-based companies, as well as General Manager in other seven Shanghai-based companies.

Robert Hoffman

Andrew Howden

Mr. Andrew Howden has been serving as Independent Director in ASLAN PHARMACEUTICALS LIMITED since February 9, 2016. He holds a Bachelor of Science and a Master's degree in Commerce both from University of New South Wales, Australia. He is also Chairman of the Board in First Pharma Pty Ltd. and True Origin Co Pty Ltd., as well as Director in Howden Family Investments Pty Ltd. and JANK Howden Pty Ltd.

Qingfeng Sun

Qingfeng Sun has been serving as Independent Director in ASLAN PHARMACEUTICALS LIMITED since April 15, 2016. Sun holds a Master of Business Administration from University of Michigan, the United States, and a Master's degree in Materials Science from Wayne State University, the United States. Sun is also Independent Director in TWi Pharmaceuticals, Inc., TAH TONG TEXTILE CO., LTD. and Wonderful Hi-Tech Co., Ltd., Chairman of the Board in FiTek Photonics Corporation, two investment companies and another company, Director in Signax Technology Capital Inc., LYTONE ENTERPRISE, INC., a development company and another investment company, as well as General Manager in SAGA UNITEK VENTURES.